BioStem Technologies, Inc.
No SEC Form 4 filings for $BSEM in the last 30 days.
See all $BSEM insider activity →BioStem Technologies' CEO and COO exercised stock options to buy 500,000 shares at $2.00 each, investing $1 million. They expressed confidence in the company's growth and plans to use the capital for sales expansion and inventory. BioStem specializes in regenerative medicine products.
BioStem Technologies (BSEM) announced the issuance of one U.S. patent and four notices of allowance for additional patent applications, expanding its intellectual property portfolio in placental and umbilical cord tissue technologies for wound care, surgical, and joint applications. The company plans to continue investing in patent protection and innovation. BioStem has over 100 patents and patent applications worldwide.
BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BSEM (BioStem Technologies, Inc.). Coverage has been balanced: 0 bullish, 4 neutral, and 0 bearish.
Recent BSEM coverage spans corporate actions, financial news and earnings.
Insider purchase signals confidence but modest size limits market impact.
The expanded patent portfolio may be viewed as a modest catalyst for future product protection and revenue growth.
The raise provides working‑capital but dilutes existing shareholders; short‑term price pressure may be modestly negative, with potential upside if funds fuel growth.
The raise adds cash but dilutes existing shareholders; short‑term price pressure is likely.
Potential dilution and additional capital could support growth but may pressure the share price if drawn.
AlphAI scores every news story that mentions BSEM with an AI model for sentiment and relevance, and aggregates insider trades from BioStem Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioStem Technologies' CEO and COO exercised stock options to buy 500,000 shares at $2.00 each, investing $1 million. They expressed confidence in the company's growth and plans to use the capital for sales expansion and inventory. BioStem specializes in regenerative medicine products.
1 min readBioStem Technologies (BSEM) announced the issuance of one U.S. patent and four notices of allowance for additional patent applications, expanding its intellectual property portfolio in placental and umbilical cord tissue technologies for wound care, surgical, and joint applications. The company plans to continue investing in patent protection and innovation. BioStem has over 100 patents and patent applications worldwide.
2 min readBioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company
2 min readBioStem Technologies (BSEM) announced a $3M private placement of 735,296 shares and warrants at $4.08 per share, with warrants exercisable at $3.83. Proceeds will be used for working capital. The offering is expected to close on September 30, 2026. H.C. Wainwright & Co. is the placement agent.
1 min readBioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the develo
2 min readBioStem Technologies (Nasdaq: BSEM) secured a $40 million Committed Equity Facility with Roth Principal Investments. The company can issue up to $40 million in shares, subject to Nasdaq rules and conditions. Proceeds will be used for working capital and general corporate purposes. BioStem filed a registration statement for the resale of shares.
1 min readBioStem Technologies (BSEM) expanded hospital access for VENDAJE and VENDAJE AC through contracts with Vizient and Premier, two large U.S. GPOs. Both products are now available for order under these contracts. The move is expected to support BioStem's commercial strategy and broaden its wound care product reach. BSEM shares closed at $3.61 on Thursday and were up 9.42% in premarket trading.
1 min readBioStem Technologies (BSEM) reported Q2 2026 revenue of $7.9M, up 29% sequentially, driven by Neox and Clarix product sales. The company raised full-year 2026 revenue guidance to $26M-$29M and uplisted to Nasdaq. BSEM also completed a $2.5M private placement and held $7.0M in cash as of Q2 2026.
2 min readBioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) — BioSt
4 min readBioStem Technologies Inc. (OTC: BSEM) said it filed a Form 10 registration statement with the SEC to register its common stock and reaffirmed plans to pursue a Nasdaq listing. The filing is not yet effective and will become effective after SEC review. Until uplisting, BSEM shares continue trading on the OTC market.
3 min read
